Stockscreener 앱 받기
2.15
8.59%
0.17
전일 마감가:
$1.98
열려 있는:
$2.05
하루 거래량:
1.16M
Relative Volume:
0.74
시가총액:
$27.12M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-28.81%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$2.05
$2.60
1주일 범위
$1.925
$3.0994
52주 변동 폭
$1.925
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
명칭
Propanc Biopharma Inc
전화
61-03-9882-0780
주소
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
PPCB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
1.78 | 1.86B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.48 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.37 | 103.78M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.3441 | 797.28M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.15 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc 주식(PPCB)의 최신 뉴스
Propanc to acquire $100M of Ethereum to accelerate pipeline - BioWorld MedTech
Propanc Biopharma announces plan to acquire $100 million of Ethereum - MSN
Propanc Biopharma’s $100M Ethereum Allocation: A Strategic Gamble or a Path to Growth? - AInvest
Propanc Biopharma, Inc. Announces $100 Million Ethereum Acquisition Plan to Enhance Growth and Diversification Strategy - Quiver Quantitative
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum - The Manila Times
$100M Ethereum Investment: Cancer Drug Developer Propanc Makes Bold Move into Crypto for Growth Strategy - Stock Titan
Propanc Biopharma Secures $4 Million in Public Offering to Advance Cancer Stem Cell Research - citybuzz -
D. Boral Capital Leads Propanc Biopharma's $4,000,000 Uplisting on Nasdaq - AInvest
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting - Newswire.com
Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials - Investing.com
Propanc Biopharma shares fall 3.26% after-hours following shareholder update on corporate developments and Phase 1B study. - AInvest
Propanc Biopharma provides shareholder update - MarketScreener
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 By Investing.com - Investing.com South Africa
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 - Investing.com Nigeria
Propanc Biopharma Provides Shareholder Update - The Manila Times
Propanc Biopharma Announces Shareholder Update and 2025/26 Forecast. - AInvest
Propanc Biopharma: Recent IPO and Up-listing to Nasdaq, Advancing Lead Asset to Phase 1B Study - AInvest
$18.1B Market Potential: Propanc's Novel Cancer Drug PRP Heads to Human Trials After Successful Nasdaq IPO - Stock Titan
Propanc Biopharma Completes Public Offering on Nasdaq - MSN
Propanc Biopharma opens at $4.00 in Nasdaq uplisting - MSN
Biotech’s Big Bang: IPOs, Uplists, and the Short Squeeze Effect - The Globe and Mail
PPCB: Is Recent Nasdaq Uplisting a Game-Changer? - StocksToTrade
Propanc Biopharma’s Surging Market Debut: What’s Next? - timothysykes.com
Stocks Moving Premarket: NBY, AUDD, PPCB And Other Gainers & Losers - RTTNews
Propanc Biopharma shares rise 34.88% premarket after closing a $4 million public offering. - AInvest
Propanc Biopharma closes public offering, uplists to NASDAQ - MSN
Propanc Biopharma Stock Soars 51.23% on Capital Raise - AInvest
Propanc Biopharma shares rise 61.58% premarket after closing a $4 million public offering. - AInvest
Why Did Propanc Biopharma Stock Soar 27.25%? - AInvest
Propanc Biopharma shares rise 52.86% premarket after closing a $4 million public offering. - AInvest
Propanc Biopharma Announces Nasdaq Uplisting, $4M Public Offering - AInvest
Propanc Biopharma shares rise 19.89% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma shares rise 21.20% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma Raises $4M Through Public Offering, Begins Trading on NASDAQ - AInvest
Propanc Biopharma's NASDAQ Uplisting: A Strategic Leap in Immuno-Oncology's High-Stakes Arena - AInvest
Propanc Biopharma closes $4 million public offering, lists on Nasdaq - Investing.com
Propanc Biopharma closes $4 million public offering, lists on Nasdaq By Investing.com - Investing.com UK
Propanc Biopharma raises $4 million in underwritten public offering. - AInvest
Propanc Biopharma Completes Public Offering, Uplisted to NASDAQ - AInvest
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ - MarketScreener
Cancer Treatment Developer Propanc Biopharma Raises $4M in IPO, Achieves Major Nasdaq Uplisting Milestone - Stock Titan
Propanc Biopharma Plunges 15.04% Amid Tariff Fears - AInvest
Why Propanc stock Is Tumbling In Premarket Today - Asianet Newsable
Precipio Announces Second Quarter 2022 Results, Revenue Up 18% YoY - AInvest
Propanc Biopharma prices $4M stock offering - MSN
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - inkl
PPCB Stock Quote - richtv.io
Propanc Biopharma Uplisting: What Lies Ahead? - timothysykes.com
Propanc Biopharma Stock (PPCB) Surges 150% After Nasdaq Uplisting and Public Offering. - AInvest
Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, and Other Gainers & Losers - AInvest
Propanc Biopharma's Nasdaq Uplisting: A Strategic Catalyst for Biotech Innovation - AInvest
Propanc Biopharma Inc (PPCB) 재무 분석
Propanc Biopharma Inc (PPCB)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):